143 related articles for article (PubMed ID: 7519483)
21. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
Momparler RL; Côté S; Eliopoulos N
Leukemia; 1997 Mar; 11 Suppl 1():S1-6. PubMed ID: 9130684
[TBL] [Abstract][Full Text] [Related]
22. Synergistic effect of cis-dichlorodiammineplatinum and 5-aza-2'-deoxycytidine on mouse leukemic cells in vivo and in vitro.
Veselý J
Int J Cancer; 1982 Jan; 29(1):81-5. PubMed ID: 6174463
[TBL] [Abstract][Full Text] [Related]
23. Effect of cytidine analogs on cell growth and differentiation on a human neuroblastoma line.
Bartolucci S; Estenoz M; de Franciscis V; Carpinelli P; Colucci GL; Augusti Tocco G; Rossi M
Cell Biophys; 1989; 15(1-2):67-77. PubMed ID: 2476228
[TBL] [Abstract][Full Text] [Related]
24. Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2'-deoxycytidine.
Momparler RL; Bouchard J; Samson J
Leuk Res; 1985; 9(11):1361-6. PubMed ID: 2417065
[TBL] [Abstract][Full Text] [Related]
25. Retinoic acid reduces the cytotoxicity of cyclopentenyl cytosine in neuroblastoma cells.
Bierau J; van Gennip AH; Leen R; Caron HN; van Kuilenburg AB
FEBS Lett; 2002 Sep; 527(1-3):229-33. PubMed ID: 12220665
[TBL] [Abstract][Full Text] [Related]
26. Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by phenylbutyrate on L1210 leukemic cells.
Lemaire M; Momparler LF; Farinha NJ; Bernstein M; Momparler RL
Leuk Lymphoma; 2004 Jan; 45(1):147-54. PubMed ID: 15061212
[TBL] [Abstract][Full Text] [Related]
27. Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2'-deoxycytidine against human leukemic cells of different phenotype.
Momparler RL; Onetto-Pothier N; Momparler LF
Leuk Res; 1990; 14(9):755-60. PubMed ID: 1700231
[TBL] [Abstract][Full Text] [Related]
28. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene.
Stegmann AP; Honders MW; Hagemeijer A; Hoebee B; Willemze R; Landegent JE
Ann Hematol; 1995 Jul; 71(1):41-7. PubMed ID: 7543292
[TBL] [Abstract][Full Text] [Related]
29. Effect of N-(phosphonacetyl)-L-aspartate on 5-azacytidine metabolism in P388 and L1210 cells.
Grant S; Rauscher F; Jakubowski A; Cadman E
Cancer Res; 1981 Feb; 41(2):410-8. PubMed ID: 6160908
[TBL] [Abstract][Full Text] [Related]
30. In vitro cytotoxic and biochemical effects of 5-aza-2'-deoxycytidine.
Momparler RL; Goodman J
Cancer Res; 1977 Jun; 37(6):1636-9. PubMed ID: 66984
[TBL] [Abstract][Full Text] [Related]
31. Pharmacology of 5-Aza-2'-deoxycytidine (decitabine).
Momparler RL
Semin Hematol; 2005 Jul; 42(3 Suppl 2):S9-16. PubMed ID: 16015507
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity and biochemical effects of cyclopentenyl cytosine in mice.
Moyer JD; Malinowski NM; Treanor SP; Marquez VE
Cancer Res; 1986 Jul; 46(7):3325-9. PubMed ID: 3708566
[TBL] [Abstract][Full Text] [Related]
33. The effect of cyclopentenyl cytosine on human SK-N-BE(2)-C neuroblastoma cells.
Slingerland RJ; Van Gennip AH; Bodlaender JM; Voûte PA; Van Kuilenburg AB
Biochem Pharmacol; 1995 Jul; 50(2):277-9. PubMed ID: 7632174
[TBL] [Abstract][Full Text] [Related]
34. 5-AZA-2'-deoxycytidine synergistic action with thymidine on leukemic cells and interaction of 5-AZA-dCMP with dCMP deaminase.
Momparler RL; Rossi M; Bouchard J; Bartolucci S; Momparler LF; Raia CA; Nucci R; Vaccaro C; Sepe S
Adv Exp Med Biol; 1986; 195 Pt B():157-63. PubMed ID: 2429505
[No Abstract] [Full Text] [Related]
35. Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer.
Lemaire M; Chabot GG; Raynal NJ; Momparler LF; Hurtubise A; Bernstein ML; Momparler RL
BMC Cancer; 2008 May; 8():128. PubMed ID: 18454857
[TBL] [Abstract][Full Text] [Related]
36. Effect of deoxycytidine on the metabolism and cytotoxicity of 5-aza-2'-deoxycytidine and arabinosyl 5-azacytosine in normal and leukemic human myeloid progenitor cells.
Bhalla K; Cole J; MacLaughlin W; Arlin Z; Baker M; Graham G; Grant S
Leukemia; 1987 Dec; 1(12):814-9. PubMed ID: 2447450
[TBL] [Abstract][Full Text] [Related]
37. Combination of azacytidine and curcumin is a potential alternative in decitabine-resistant colorectal cancer cells with attenuated deoxycytidine kinase.
Hosokawa M; Seiki R; Iwakawa S; Ogawara KI
Biochem Biophys Res Commun; 2021 Nov; 578():157-162. PubMed ID: 34571370
[TBL] [Abstract][Full Text] [Related]
38. Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity.
Gourdeau H; Bibeau L; Ouellet F; Custeau D; Bernier L; Bowlin T
Cancer Chemother Pharmacol; 2001 Mar; 47(3):236-40. PubMed ID: 11320667
[TBL] [Abstract][Full Text] [Related]
39. Cyclopentenyl cytidine analogue. An inhibitor of cytidine triphosphate synthesis in human colon carcinoma cells.
Glazer RI; Knode MC; Lim MI; Marquez VE
Biochem Pharmacol; 1985 Jul; 34(14):2535-9. PubMed ID: 4015694
[TBL] [Abstract][Full Text] [Related]
40. 5-aza-2'-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation.
Momparler RL; Bouchard J; Onetto N; Rivard GE
Leuk Res; 1984; 8(2):181-5. PubMed ID: 6201685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
